What is Impel Pharmaceuticals?
Impel Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to the development of transformative intranasal drug treatments for patients suffering from central nervous system disorders. By utilizing its proprietary Precision Olfactory Delivery (POD) technology, the company aims to bypass the blood-brain barrier, offering a more efficient delivery mechanism for therapeutic agents. This innovative approach positions Impel as a key player in the neurology sector, where traditional oral or systemic delivery methods often face significant limitations in efficacy and patient compliance. The company's market position is defined by its ability to bridge the gap between complex scientific research and scalable, patient-centric medical solutions.
How much funding has Impel Pharmaceuticals raised?
Impel Pharmaceuticals has raised a total of $346.6M across 7 funding rounds:
Series B
$12M
Debt
$1.1M
Series C
$36M
Series D
$67.5M
Stock Offering
$80M
Debt
$50M
Other Financing Round
$100M
Series B (2015): $12M with participation from 3M New Ventures
Debt (2016): $1.1M, investors not publicly disclosed
Series C (2016): $36M supported by Vivo Capital, venBIO, and 5AM Ventures
Series D (2018): $67.5M featuring Vivo Capital, KKR & Co. (Kohlberg Kravis Roberts & Co.), venBio, 5AM Ventures, and Norwest Venture Partners
Stock Issuance/Offering (2021): $80M, investors not publicly disclosed
Debt (2021): $50M with participation from Silicon Valley Bank
Other Financing Round (2022): $100M led by Oaktree
Key Investors in Impel Pharmaceuticals
Vivo Capital
Vivo Capital is a global healthcare investment firm founded in 1996, specializing in private and public equity as well as venture capital within the life sciences sector.
KKR & Co.
KKR is a leading global investment firm that manages a broad range of alternative asset classes, focusing on long-term value creation for its portfolio companies.
venBio
venBio is a life sciences investment firm that partners with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs.
What's next for Impel Pharmaceuticals?
With the successful closure of its most recent financing, Impel Pharmaceuticals is well-positioned to scale its commercial infrastructure and accelerate the commercialization of its CNS portfolio. The strategic focus will likely shift toward expanding market penetration and optimizing supply chain logistics to meet the growing demand for its intranasal therapies. Furthermore, the company is expected to continue its investment in R&D to explore new therapeutic applications for its POD platform, potentially diversifying its pipeline to address a broader range of neurological conditions. As the firm matures, the emphasis will remain on achieving sustainable revenue growth while maintaining the rigorous scientific standards that have attracted top-tier institutional backing.
See full Impel Pharmaceuticals company page
